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Abstract: The present study analyzed the expression and clinical role of the protein of 
regenerating  liver  (PRL)  phosphatase  family  in  ovarian  carcinoma.  PRL1-3  mRNA 
expression was studied in 184 tumors (100 effusions, 57 primary carcinomas, 27 solid 
metastases)  using  RT-PCR.  PRL-3  protein  expression  was  analyzed  in  157  tumors  by 
Western blotting. PRL-1 mRNA levels were significantly higher in effusions compared to 
solid  tumors  (p < 0.001),  and  both  PRL-1  and  PRL-2  were  overexpressed  in  pleural 
compared to peritoneal effusions (p = 0.001). PRL-3 protein expression was significantly 
higher  in  primary  diagnosis  pre-chemotherapy  compared  to  post-chemotherapy  disease 
recurrence  effusions  (p = 0.003).  PRL-1  mRNA expression  in  effusions  correlated  with 
longer overall survival (p = 0.032), and higher levels of both PRL-1 and PRL-2 mRNA 
correlated  with  longer  overall  survival  for  patients  with  pre-chemotherapy  effusions 
(p = 0.022  and  p = 0.02,  respectively).  Analysis  of  the  effect  of  laminin  on  PRL-3 
expression in ovarian carcinoma cells in vitro showed dose-dependent PRL-3 expression in 
response  to  exogenous  laminin,  mediated  by  Phospholipase  D.  In  contrast  to  previous 
studies associating PRL-3 with poor outcome, our data show that PRL-3 expression has no 
clinical role in ovarian carcinoma, whereas PRL-1 and PRL-2 expression is associated with 
longer survival, suggesting that PRL phosphatases may be markers of improved outcome 
in this cancer. 
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1. Introduction 
Events  in  cancer  progression  and  metastasis  remain  less  well-defined  than  those  involved  in 
oncogenesis, despite the fact that tumor metastasis is the major factor causing cancer mortality. The 
indication that the altered regulation of specific protein tyrosine phosphorylation events and signaling 
pathways  may  characterize  metastatic  cells  is  exciting  and  may  be  the  basis  for  new  anticancer 
strategies that would inhibit tumor growth and metastasis.  
Protein  tyrosine  phosphatases  (PTP)  and  tyrosine  kinases  regulate  vital  intracellular  signaling 
pathways,  controlling  most  cellular  activities  [1,2].  Aberrant  expression  and  activation  of  these 
enzymes are often causative factors in cancer [3,4].  
Protein of regenerating liver-3 (PRL-3) and two closely-related PTPs, PRL-1 and PRL-2, comprise 
a novel sub-class (the PRL-PTPs) within the large PTP super-family. PRL-1 was identified as  an 
immediate-early gene expressed in mitogen-stimulated cells and regenerating liver [5] and later shown 
to be a PTP [6]. Subsequently, PRL-2 and PRL-3 were discovered and were shown to share high 
homology in their amino acid sequence with PRL-1 and to have PTP activity [7–9]. 
Several recent  observations showed that  PRL phosphatases,  especially  PRL-3,  may play causal 
roles in growth regulation, proliferation, cell motility, and invasion [10–12]. Saha et al. first linked 
PRL-3 with the metastasis of human cancer, reporting that elevated PRL-3 expression was detected in 
all  liver  metastases  from  colorectal  cancer  [13].  Accumulated  evidence  further  demonstrated  that  
PRL-3 is associated with metastasis of multiple tumor types [12,14–19], and has been validated as a 
potential therapeutic target for metastasis. 
Ovarian carcinoma (OC), the most lethal gynecological cancer, ranks fifth in cancer related-deaths 
among  women  and  is  frequently  referred  to  as  the  “silent  killer”,  with  the  majority  of  patients 
diagnosed  with  advanced-stage  (FIGO  stages  III–IV)  disease  [20].  We  previously  reported  that 
expression of the phosphatase PAC-1 in OC effusions is associated with poor outcome [21].  
In the present study, we examined the expression of PRLs in primary OC, solid metastases and 
pleural and peritoneal effusions. In view of our previous observation that dual-specificity phosphatases 
(DUSP), negative regulators of the mitogen-activated protein kinase (MAPK) family, are affected by 
laminin signaling [22], we additionally investigated the relationship between PRL-3 and exposure of 
OC  cells  to  laminin  in  vitro.  Our  results  show  that  PRL-1  mRNA  levels  are  higher  in  effusions 
compared  to  solid  tumors  and  that  both  PRL-1  and  PRL-2  are  more  highly  expressed  in  pleural 
compared to peritoneal effusions. Nevertheless, higher PRL-1 and PRL-2 expression in effusions is 
associated with longer overall survival. In contrast to previous studies in which PRL-3 has been shown 
to be a marker of poor prognosis in other malignancies, our data suggest that its expression in OC has 
no clinical role. 




2. Materials and Methods 
2.1. Tumors and Patients 
The material analyzed in the present study consisted of 100 effusions (72 peritoneal, 28 pleural), 
57 primary  carcinomas,  and  27  solid  metastases,  submitted  for  routine  diagnostic  purposes  to  the 
Division of Pathology, Norwegian Radium Hospital, in the period 1996–2005. Effusions were tapped 
from 90 patients, of whom 81 had one effusion, eight had two effusions, and one had three effusions. 
Effusions were obtained from patients diagnosed with OC (n = 74), predominantly of the serous type, 
primary  peritoneal  serous  carcinoma  (n = 11)  or  tubal  serous  carcinoma  (n = 5).  Due  to  their  
closely-linked histogenesis and phenotype, all these tumors are referred to as OC in the following 
sections. Primary carcinomas and solid metastases were each a single lesion from each patient. The 
latter  were  predominantly  omental  lesions.  The  majority  of  tumors  from  different  sites  were  not 
patient-matched. Clinicopathologic data are summarized in Table 1. 
Table 1. Clinicopathologic data of the study cohort. 
Parameter 
Material (Number of Patients) 
Effusions (90)  Primary (57)  Metastasis (27) 
Age  Mean (range)  61 (34–79)  60 (31–84)  63 (47–80) 
FIGO Stage 
I  0  4  2 
II  1  5  0 
III  46  27  16 
IV  43  13  9 
NA
 a  0  8  0 
Grade 
I  9  9  1 
II  21  15  5 
III
 b  51  26  20 




≤1 cm  32  34  14 
>1 cm  44  14  13 
NA  14  9  0 
Histology 
Serous  75  40  19 
Mucinous  1  0  0 
Clear cell  4  3  2 
Endometrioid  1  7  3 
Mixed epithelial  4  3  0 
Undifferentiated  2  0  3 
NA  3  4  0 
a Not available; 
b including 9 clear cell carcinomas. 
Effusions were all received in the fresh non-fixed state immediately after tapping. Specimens were 
centrifuged and pellets were fresh-frozen at −70 ° C in RPMI 1640 medium supplemented with 50% 




and H&E-stained  cell  block  sections  were  reviewed  by  a  surgical  pathologist  experienced  in 
cytopathology (BD). Diagnoses were established using morphology and immunohistochemistry.  
OC biopsies were similarly snap-frozen. Frozen sections from all tumors were evaluated for the 
presence  of a  >50% tumor  component  and  absence  of necrosis.  H&E-stained sections  from  these 
tumors were reviewed to establish tumor type and histological grade. 
2.2. RT-PCR Analysis 
Total RNA was extracted using a commercial kit (Tri Reagent; Sigma-Aldrich, St. Louis, MO, 
U.S.),  and  0.5  μg  of  total  RNA  were  reverse-transcribed  using  M-MLV  Reverse  Transcriptase 
(Promega, Madison, WI, U.S.) with incubation for 2 h at 37 ° C, followed by 5 min at 95 ° C, and 
diluted 1:5 with RNase-free water. Reverse-transcriptase polymerase chain reaction (RT-PCR) analysis 
was  performed  on  cDNA  samples  with  a  DNA  thermal  cycler  (Eppendorf  Mastercycler  gradient; 
Eppendorf, Hamburg, Germany) using primer sets detecting PRL and 28S ribosomal RNA. Primer 
sequences and cycle parameters are detailed in Tables 2 and 3, respectively. RNA from HT-1080 cells 
served as internal controls.  
Table 2. Primer sequences. 


















200  [24] 
Antisense: 5’-GGATTCTGACTTAGAGGCGTTCAGT-3' 
Table 3. Cycle parameters. 
Gene  Heating  Denaturation  Annealing  Extension  No. of Cycles 
PRL-1  94 ° C, 5 min  94 ° C, 30 s  60 ° C, 30 s  60 ° C, 30 s  32 
PRL-2  94 ° C, 5 min  94 ° C, 30 s  60 ° C, 30 s  72 ° C, 30 s  32 
PRL-3  94 ° C, 5 min  94 ° C, 30 s  58 ° C, 1 min  72 ° C, 90 s  32 
28s  94 ° C, 5 min  94 ° C, 15 s  63 ° C, 20 s  72 ° C, 10 s  31 
Products were separated on 1.5% agarose gels, isolated using the Invisorb
® Spin DNA extraction kit 
(Invitek GmbH, Berlin, Germany) and sequenced. Gels were photographed by the KODAK EDAS 290 
system. Densitometer analysis of films was performed using a computerized image analysis (NIH 
IMAGE 1.63) program. PRL-1, PRL-2 and PRL-3 mRNA levels were established by calculating the 
target molecule/28S ratio (all cases scored for band intensity compared to control) [24]. Expression 
intensity of ≤5% of control levels was interpreted as negative. Measurements were made in the linear 




2.3. Western Blotting 
Cells and tissues were lysed in 1% NP-40, 20 mM Tris HCl (pH 7.5), 137 mM NaCl, 0.5 mM 
EDTA,  10%  glycerol,  1%  protease  inhibitor  cocktail  (Sigma-Aldrich)  and  0.1%  SDS.  Following 
centrifugation, the supernatant was collected and protein content was evaluated by the Bradford assay. 
30 μg  from  each  sample  under  reducing  conditions  were  loaded  into  each  lane  and  separated  by 
electrophoresis  on  a  12%  SDS  polyacrylamide  gel.  Following  electrophoresis,  proteins  were 
transferred to Immobilon transfer membranes (Millipore, Billerica, MA, U.S.). Nonspecific binding 
was blocked by incubation with TBST (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% Tween 20) 
containing 5% skim milk for 1 h at room temperature. Membranes were subsequently incubated with 
antibodies against α-tubulin (Sigma-Aldrich) and PRL-3 (Genesis Biotech Inc., Taiwan). Antibody 
was  detected  using peroxidase-conjugated AffiniPure  goat  anti-rabbit  IgG or  goat anti-mouse  IgG 
(Jackson ImmunoResearch, West Grove, PA, U.S.) and enhanced chemiluminescence Western blotting 
detection reagents (Thermo Fisher Scientific, Waltham, MA, U.S.). HT-1080 cells served as controls. 
2.4. Cell Lines and Culture Conditions 
The  ES-2, OVCAR-8,  A2780 and  OVCAR-3 OC  cell lines were used in this study. ES-2  and 
OVCAR-3 cells were cultured in DMEM 4.5 GR l
−1 D-Glucose, while OVCAR-8 and A2780 cells 
were cultured in RPMI, all supplemented with 10% fetal calf serum, penicillin, essential amino acids 
and streptomycin (Biological Industries, Beit-Haemek, Israel). 
2.5. Regulation of PRL-3 Expression 
The ES-2, OVCAR-8, A2780 and OVCAR-3 OC cell lines were exposed to various concentrations 
of laminin (1–20 μg/mL) in the presence of 1-propanol or 2-propanol (0.5%) for 6 h and the protein 
level of PRL-3 was evaluated by Western blot analysis. 
2.6. Statistical Analysis 
Data were analyzed using the SPSS-PC package, version 16.0 (Chicago, IL, U.S.) comparative 
analyses  of  results  in  effusions,  primary  and  solid  metastases  using  PCR  and  Western  Blot  were 
performed using the Kruskal-Wallis  H test  (analysis of  all three sites)  or  Mann-Whitney test  (for 
analysis of two sites).  
PRL expression levels in effusions were analyzed for association with clinicopathologic parameters 
and survival. Clinicopathologic parameters were grouped as follows: Age: ≤60 vs. >60 years; grade:  
1–2  vs.  3;  effusion  site:  peritoneal  vs.  pleural;  FIGO  stage:  IIIc  vs.  IV;  chemotherapy  status:  
pre-  vs.  post-chemotherapy  specimens;  residual  disease  volume  (≤1 cm  vs.  >1 cm);  response  to 
chemotherapy  for  primary  disease  and  for  disease  recurrence:  complete  vs.  partial  response/stable 
disease/progression. Progression-free and overall survival (PFS; OS) were calculated from the date of 
the  last  chemotherapy  treatment/diagnosis  to  the  date  of  recurrence/death  or  last  follow-up, 
respectively.  Univariate  survival  analyses  of  PFS  and  OS  were  executed  using  the  Kaplan-Meier 




than  median  expression.  Multivariate  analyses  of  OS  were  performed  using  the  Cox  proportional 
hazard model. 
3. Results 
3.1. PRL Enzyme Expression at Various Anatomic Sites 
Previous  studies  have  shown  involvement  of  PRL  enzymes  in  tumor  progression  of  different 
malignancies. Our objective was to investigate whether PRLs are expressed in OC and to analyze 
potential anatomic site-related differences in their expression level. 
PRL-1  and  PRL-2  mRNA  was  detected  in  all  100  effusions  and  27  solid  metastases  and  in 
56/57 primary  carcinomas  (Figures  1A,  B). PRL-3  mRNA was  detected in  all effusions  and solid 
metastases and in 53/57 primary carcinomas (Figure 1C). PRL-3 protein was found in 86/97 effusions, 
33/41 primary carcinomas and 16/19 solid metastases (Figure 1D). Comparative analysis of expression 
levels obtained in quantitative analysis of band size and intensity showed significantly higher PRL-1 
mRNA expression in effusions compared to solid tumors (p < 0.001; Figure 1E). PRL-2 and PRL-3 
mRNA and PRL-3 protein expression was comparable at all anatomic sites (p > 0.05; data not shown). 
Additionally, PRL-1 and PRL-2 mRNA expression was significantly higher in pleural compared to 
peritoneal effusions (p = 0.001 for both; Figure 1F), with a similar trend for PRL-3 mRNA (p = 0.085) 
and PRL-3 protein (p = 0.054).  
Figure  1.  PRL  expression  at  different  anatomic  sites  in  ovarian  carcinoma  (OC).  
(A–C)  Representative  gels  showing  PRL-1,  PRL-2  and  PRL-3  mRNA  expression  by  
RT-PCR;  (D)  PRL-3  protein  expression  by  Western  blotting;  P = primary  carcinoma, 
M = solid metastasis, E = effusion; (E) Differential expression of PRL-1 mRNA in OC 
effusions compared to primary carcinomas and solid metastases (Kruskal-Wallis H Test, 
p < 0.001); (F) Differential expression of PRL-1 and PRL-2 mRNA in pleural compared to 
peritoneal effusions (Mann-Whitney U Test, p = 0.001). 








Figure 1. Cont. 
 
3.2. The Clinical Significance of PRL Enzyme Expression  
PRL  mRNA  and  PRL-3  protein  expression  levels  were  analyzed  for  association  with 
clinicopathologic  parameters.  No  significant  associations  were  observed  between  PRL  mRNA 
expression  and  chemotherapy  status,  patient  age,  histological  grade,  FIGO  stage,  residual  disease 
volume or response to chemotherapy at diagnosis or first disease recurrence. However, PRL-3 protein 
expression was higher in pre-chemotherapy compared to post-chemotherapy effusions (p = 0.003), a 
finding that was significantly related to previous treatment with platinum agents (p = 0.024), but was 
only  as  a  trend  with  respect  to  paclitaxel  treatment  (p = 0.056).  PRL-3  protein  expression  was 
unrelated to the other clinicopathologic parameters (p > 0.05). 
Survival data were available for 49 of the 57 patients with primary OC. The follow-up period for 
these patients ranged from 3–91 months (mean = 32 months, median = 31 months). At last follow-up, 
20 patients were alive without disease, eight were alive with disease and 20 were dead of disease. One 
patient was lost to follow-up. PFS ranged from 0-65 months (mean = 16 months, median = 10 months). 
PRL1-3 mRNA and PRL-3 protein expression in primary OC were unrelated to OS or PFS in this 
cohort (p > 0.05; data not shown). 
 




Figure 2. PRL-1 and PRL-2 mRNA expression in OC effusions is associated with longer 
overall survival (OS). (A) Kaplan-Meier survival curve showing the association between 
PRL-2  mRNA  expression  and  OS  in  the  entire  effusion  cohort  (n = 90).  Patients  with 
effusions having higher than median PRL-2 mRNA levels (n = 45; solid line) had mean OS 
of 39 months compared to 29 months for patients with lower than median expression levels 
(n = 45, dashed line; p = 0.032); (B) Kaplan-Meier survival curve showing the association 
between PRL-1 mRNA expression and OS for women with pre-chemotherapy effusions 
(n = 44). Patients with effusions having higher than median PRL-1 mRNA levels (n = 26; 
solid line) had mean OS of 39 months compared to 23 months for patients with lower than 
median expression levels (n = 18, dashed line; p = 0.022); (C) Kaplan-Meier survival curve 
showing  the  association  between  PRL-2  mRNA  expression  and  OS  for  women  with  
pre-chemotherapy effusions (n = 44). Patients with effusions having higher than median 
PRL-2 mRNA levels (n = 26; solid line) had mean OS of 39 months compared to 24 months 
for patients with lower than median expression levels (n = 18, dashed line; p = 0.02). 




Survival data were available for all 90 patients with OC effusions. The follow-up period for these 
patients  ranged  from  1–105  months  (mean = 34  months,  median = 27  months).  At  last  follow-up, 
one patient  was  alive  without  disease,  one  was  alive  with  disease  and  87  were  dead  of  disease. 
One patient  died  of  unrelated  causes.  PFS  ranged  from  0–82  months  (mean = 8  months, 
median = 5 months).  In  univariate  survival  analysis  of  the  entire  cohort,  higher  PRL-2  mRNA 
expression was associated with longer OS (p = 0.032; Figure 2A), with a similar trend for PRL-1 
(p = 0.107) and PRL3 protein (p = 0.105). PRL-3 mRNA expression was unrelated to survival.  
In  univariate  survival  analysis  of  patients  with  primary  diagnosis  pre-chemotherapy  effusions, 
higher levels of both PRL-1 and PRL-2 mRNA were significantly associated with longer OS (p = 0.022 
and p = 0.02, respectively; Figures 2B,C), with a similar trend for PRL-3 (p = 0.093). PRL3 protein 
expression was unrelated to survival (p > 0.05).  
In  univariate survival  analysis of patients with disease  recurrence post-chemotherapy effusions, 
none of the studied molecules was significantly associated with OS.  
PRL expression in effusions was unrelated to PFS in any of these patient groups.  
Multivariate Cox analysis of OS was performed for the entire effusion cohort, as well as for patients 
with primary diagnosis effusions. The parameters entered into the former analysis consisted of PRL-1 
and PRL-2 mRNA expression, PRL-3 protein expression and the two clinical parameters that were 
significantly  associated  with  OS  in  univariate  analysis,  response  to  chemotherapy  at  diagnosis 
(p < 0.001) and at first disease recurrence (p = 0.001). Only chemoresponse at diagnosis (p = 0.009) 
and at first disease recurrence (p = 0.001) was an independent prognostic marker.  
The parameters entered in the multivariate Cox analysis of OS for patients with primary diagnosis 
effusions consisted of PRL-1, PRL-2 and PRL-3 mRNA expression, as well as residual disease volume 
(p = 0.163)  and  response  to  chemotherapy  at  diagnosis  (p = 0.004)  and  at  first  disease  recurrence 
(p = 0.021). Similarly to the entire cohort, only chemoresponse at diagnosis (p = 0.016) and at first 
disease recurrence (p = 0.01) was an independent prognostic marker.  
3.3. PRL-3 Regulation 
The molecular mechanism and regulation of PRL-3 is not clear yet. It has been suggested to be 
involved in several intracellular pathways regulating cellular proliferation and tumor dissemination. 
Our  previous  studies  have  shown  a  direct  correlation  between  cellular  phosphatases  and  laminin 
signaling in malignant melanoma [22]. Therefore, we examined the effect of exogenous laminin on the 
expression  of  PRL-3  protein  in  OC  cells  in  vitro.  Our  results  show  a  significant  dose-dependent 
expression of PRL-3 in response to exogenous laminin (Figure 3A). In previous studies, we have 
shown that laminin signaling involves activation of phospholipase D (PLD) enzymes [25,26]. We 
repeated the experiments in the presence of primary and secondary alcohol, known modulators of PLD 
signal transduction. Indeed, 1-propanol inhibited the laminin-induced PRL-3 protein expression while 
2-propanol did not show any effect on the expression of the protein, indicating the involvement of PLD 
in this process (Figure 3B).  




Figure 3. PRL-3 expression in response to laminin stimulation. (A) OVCAR-8 OC cells 
were  exposed  to  different  concentrations  of  exogenous  laminin  for  6  h  and  protein 
expression  evaluated;  (B)  PRL-3  expression  in  presence  of  primary  and  secondary 
alcohols.  OVCAR-8  OC  cells  were  exposed  to  various  laminin  concentrations  in  the 
presence of 1-propanol and 2-propanol and protein expression evaluated. 
 
4. Discussion 
The  value  of PRL-3  as  a potential therapeutic  target  in cancer has been  evaluated in different 
malignancies in recent years, with the majority of studies focusing on metastatic disease [12,14,18,27–29]. 
The PRL PTPs exhibit different tissue expression levels and patterns. In normal human adult tissues, 
PRL-3  is  expressed  predominantly  in  the  heart  and  striated  and  smooth  muscle  cells,  with  lower 
expression in the pancreas, and this expression pattern is distinct from the wider expression of PRL-1 
and PRL-2 in brain, liver, and kidney [10].  
Analysis of genes expressed in normal colorectal epithelia, primary colorectal carcinomas, and liver 
metastases revealed that PRL-3 expression was lower in primary tumors compared to metastases and 
essentially  undetectable  in  normal  colorectal  epithelia,  suggesting  that  elevated  levels  of  PRL-3 
contribute to or are a consequence of tumor progression [13].  
In contrast to the above-mentioned studies of various solid tumors, in which PRL-3 has been shown 
to  be  associated  with  poor  prognosis,  our  results  show  that  PRL-3  mRNA  and  PRL-3  protein 
expression have no clinical role in OC. Furthermore, PRL-3 protein expression is downregulated along 
tumor  progression,  as  evidenced  by  the  lower  expression  of  this  protein  in  disease  recurrence 
compared to primary diagnosis effusions. A possible explanation for this phenomenon could be the 
unique  form  of  OC  tumor  progression.  We  recently  showed  that  OC  effusions  deviate  from  the 
epithelial-to-mesenchymal (EMT)-like processes present in most solid tumors by presenting partial 
mesenchymal-to-epithelial (MET)-like characteristics [30]. 
Of special interest is the significantly higher expression of PRL-1 mRNA in OC effusions compared 
to both primary carcinomas and solid metastases, suggesting that this phosphatase has an important 
regulatory role at this anatomic site. Further, we found a correlation between both PRL-1 and PRL-2 
mRNA levels in OC effusions and longer OS, supporting the relevance of this family for OC effusion 
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biology. To our best knowledge, this is the first description of such a correlation. The fact that this 
finding did not reach significance at multivariate analysis owes at least to some extent to the strong 
clinical role of chemoresponse in our cohort and in OC in general. 
As shown by previous studies, PRL-3 is a multitasking phosphatase involved in modulating cancer 
metastasis. However, the mechanisms of PRL-3 action and regulation are poorly understood since 
neither the substrates nor the signaling pathways have been characterized. It was shown in vitro that 
PRL-3  might  act  as  an  upstream  regulator  of  the  phosphatase  and  tensin  homologue  deleted  on 
chromosome 10 (PTEN)-phosphoinositide 3-kinase (PI3K) signaling network [31]. Others have shown 
PRL-3 association with the integrin β1-ERK1/2 phosphorylation pathway [32]. Recently, it has been 
suggested that PRL-1 and PRL-3 may downregulate p53 via the activation of PIRH2 and MDM2 [33].  
Our group has not previously studied the molecular interactions of PRL in cancer. However, we 
previously reported on the downregulation of the DUSP family member MKP-1, with concomitant 
upregulation of PAC-1, another DUSP member, in A375SM melanoma cells following exposure to the 
extracellular  protein  laminin  [22],  leading  us  to  hypothesize  that  laminin  may  regulate  other 
phosphatases.  In  the  present  study,  we  show  that  PRL-3  may  indeed  be  induced  in  OC  cells  by 
laminin, and that this induction is mediated, at least partially, via activation of PLD. 
5. Conclusion 
In contrast to previous studies indicating that PRL-3 is a marker of more aggressive clinical course, 
our data show that the clinically relevant PRL members in metastatic OC are PRL-1 and PRL-2, both 
of which are associated with less aggressive disease. These data suggest that PRL members may have 
different cellular functions in OC compared to other cancers, which are yet to be characterized. The 
upregulation of PRL-1 in effusions compared to solid lesions provides further evidence of the unique 
biology of OC cells at this anatomic site. 
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